Compounds > 4-methyl-3-hydroxyanthranilic acid
Page last updated: 2024-12-07
4-methyl-3-hydroxyanthranilic acid
Description
4-Methyl-3-hydroxyanthranilic acid (4M3HA) is an important intermediate in the biosynthesis of the vitamin riboflavin. It is synthesized from chorismate by the enzyme 4-methyl-3-hydroxyanthranilate synthase (Mhas). 4M3HA is also a substrate for the enzyme riboflavin synthase, which catalyzes the final step in riboflavin biosynthesis. The importance of 4M3HA lies in its role as a precursor to riboflavin, an essential nutrient for human health. Riboflavin is a coenzyme for several important metabolic enzymes, including those involved in energy production, DNA synthesis, and red blood cell formation. Deficiencies in riboflavin can lead to a variety of health problems. Research on 4M3HA focuses on understanding its role in riboflavin biosynthesis, developing methods for its synthesis, and exploring its potential as a therapeutic agent. 4M3HA has been shown to have antioxidant and anti-inflammatory properties. However, further research is needed to determine its safety and efficacy as a therapeutic agent.'
4-methyl-3-hydroxyanthranilic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3-hydroxy-4-methylanthranilic acid : An aminobenzoic acid that is anthranilic acid substituted by a hydroxy group at position 3 and a methyl group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 95222 |
CHEBI ID | 16116 |
SCHEMBL ID | 1005989 |
MeSH ID | M0106322 |
Synonyms (18)
Synonym |
CHEBI:16116 |
3,4-cresotic acid, 2-amino- |
2-amino-3-hydroxy-4-methylbenzoic acid |
4-methyl-3-hydroxyanthranilic acid |
benzoic acid, 2-amino-3-hydroxy-4-methyl- |
552-14-7 |
nsc24344 |
3-hydroxy-4-methylanthranilic acid |
nsc-24344 |
C03986 , |
unii-u5azk5iee7 |
nsc 24344 |
u5azk5iee7 , |
SCHEMBL1005989 |
DTXSID60203691 |
OYZONAXDAWHDMN-UHFFFAOYSA-N |
2-amino-3,4-cresotic acid |
Q27098385 |
Roles (1)
Role | Description |
bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
monohydroxybenzoic acid | Any hydroxybenzoic acid having a single phenolic hydroxy substituent on the benzene ring. |
aminobenzoic acid | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 6 (60.00) | 18.7374 |
1990's | 2 (20.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.82
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.82 (24.57) | Research Supply Index | 2.40 (2.92) | Research Growth Index | 4.21 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |